Quintana, Elsa
Revolution Medicines (United States)
6 papers on CoChatORCID 0000-0002-4123-1695
Most cited papers
- Verified
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 369
- Verified
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 343
- Verified
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature
Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling
Cited by 209
- Verified
Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Jiang, L., Menard, M., Weller, C., Wang, Z., Burnett, L., Aronchik, I., Steele, S., Flagella, M., Zhao, R., Evans, J. W. W., et al. (2023) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 76
- Verified
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer
Araujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 70
- Verified
Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
Koltun, E. S., Rice, M. A., Gustafson, W. C., Wilds, D., Jiang, J., Lee, B. J., Wang, Z., Chang, S., Flagella, M., Mu, Y., et al. (2022) · Cancer Research
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free